Get the Stockscreener App
34.02
1.37%
0.46
Ideaya Biosciences Inc stock is traded at $34.02, with a volume of 845.83K.
It is up +1.37% in the last 24 hours and up +6.48% over the past month.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
See More
Previous Close:
$33.56
Open:
$33.77
24h Volume:
845.83K
Relative Volume:
0.76
Market Cap:
$2.98B
Revenue:
$23.38M
Net Income/Loss:
$-155.22M
P/E Ratio:
-15.53
EPS:
-2.19
Net Cash Flow:
$-134.36M
1W Performance:
-5.16%
1M Performance:
+6.48%
6M Performance:
+52.69%
1Y Performance:
+31.96%
1-Day Range:
$33.12
$34.25
1-Week Range:
$33.12
$37.08
52-Week Range:
$13.45
$37.08
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Name
Ideaya Biosciences Inc
Sector
Industry
Phone
650-443-6209
Address
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare IDYA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
34.02 | 2.94B | 23.38M | -155.22M | -134.36M | -2.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | Truist | Buy |
| Sep-18-25 | Initiated | Guggenheim | Buy |
| Sep-04-25 | Initiated | Barclays | Overweight |
| Sep-04-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jul-22-25 | Initiated | TD Cowen | Buy |
| Jul-10-25 | Resumed | Goldman | Neutral |
| Jun-26-25 | Initiated | Wells Fargo | Overweight |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Nov-05-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-15-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-08-24 | Initiated | Mizuho | Outperform |
| Mar-08-24 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | SVB Securities | Outperform |
| May-24-23 | Initiated | Goldman | Buy |
| Apr-24-23 | Upgrade | Stifel | Hold → Buy |
| Mar-23-23 | Initiated | Berenberg | Buy |
| Feb-28-23 | Initiated | RBC Capital Mkts | Outperform |
| Dec-28-22 | Initiated | CapitalOne | Overweight |
| Oct-27-22 | Initiated | Citigroup | Buy |
| Aug-15-22 | Downgrade | Stifel | Buy → Hold |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Mar-10-22 | Upgrade | Stifel | Hold → Buy |
| Sep-23-21 | Initiated | Stifel | Hold |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Mar-11-21 | Initiated | Guggenheim | Buy |
| Oct-07-20 | Initiated | Wedbush | Outperform |
| Sep-01-20 | Initiated | Northland Capital | Outperform |
| Jul-13-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-17-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-06-20 | Initiated | H.C. Wainwright | Buy |
| Mar-13-20 | Initiated | ROTH Capital | Buy |
| Oct-17-19 | Initiated | Oppenheimer | Outperform |
| Sep-10-19 | Initiated | Robert W. Baird | Outperform |
| Jun-17-19 | Initiated | Citigroup | Buy |
| Jun-17-19 | Initiated | JP Morgan | Neutral |
| Jun-17-19 | Initiated | Jefferies | Buy |
View All
Ideaya Biosciences Inc Stock (IDYA) Latest News
Ideaya Biosciences to regain rights for two programs as GSK ends partnership - Investing.com India
Redmile Group LLC Sells 102,106 Shares of IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA financials not impacted by GSK termination, says Mizuho - MSN
IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma - BioSpace
IDEAYA Hits Full Enrolment In Pivotal Trial Of Darovasertib For Metastatic Uveal Melanoma - RTTNews
IDEAYA Biosciences Completes Targeted Full Enrollment in Trial of Darovasertib With Pfizer's Crizotinib - marketscreener.com
IDEAYA completes enrollment for pivotal cancer drug trial By Investing.com - Investing.com Australia
IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers - BioSpace
Stempoint Capital LP Purchases 98,886 Shares of IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA Biosciences submits IND for novel cancer drug IDE574 By Investing.com - Investing.com Australia
Ideaya Biosciences announces IND submission for IDE574 - marketscreener.com
Ideaya Biosciences Announces Ind Submission For Ide574 - TradingView — Track All Markets
IDEAYA Biosciences (Nasdaq: IDYA) submits IND for IDE574, a KAT6/7 inhibitor in breast and lung cancer - Stock Titan
Hsbc Holdings PLC Has $804,000 Stake in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
JPMorgan Chase & Co. Purchases 115,827 Shares of IDEAYA Biosciences, Inc. $IDYA - MarketBeat
Trading the Move, Not the Narrative: (IDYA) Edition - news.stocktradersdaily.com
Ideaya disclosed termination of GSK license agreement - MSN
GSK (GSK) Plans to End Agreement with Ideaya Biosciences - GuruFocus
IDEAYA Biosciences (NASDAQ:IDYA) Reaches New 52-Week HighHere's Why - MarketBeat
Federated Hermes Inc. Has $97.27 Million Holdings in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
GSK ends collaboration with IDEAYA for two candidates - MSN
Can IDEAYA Biosciences Stock Hold Up When Markets Turn? - Trefis
IDEAYA Biosciences, Inc. $IDYA Stock Holdings Lifted by New York State Common Retirement Fund - MarketBeat
Schroder Investment Management Group Has $4.64 Million Holdings in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
Why IDEAYA Biosciences Shares Are Under Pressure - TipRanks
GlaxoSmithKline to end collaboration with Ideaya Biosciences on two clinical programs - Investing.com Nigeria
IDEAYA Biosciences Shares Climb After FDA Clears Bispecific ADC Candidate - MSN
IDEAYA Biosciences Receives Termination Notice from GSK - TradingView — Track All Markets
Ideaya Biosciences stock hits 52-week high at 36.57 USD By Investing.com - Investing.com Nigeria
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance - Business Wire India
Will IDEAYA Biosciences Inc. (30J) stock profit from automation wave2025 Short Interest & Advanced Swing Trade Entry Plans - Newser
IDE034, a Bispecific ADC Licensed by Biocytogen Pharmaceuticals Co., Ltd to IDEAYA Biosciences, Inc, Receives FDA IND Clearance - marketscreener.com
IDEAYA Biosciences (Nasdaq: IDYA) gets FDA IND for IDE034 Phase 1 solid tumor study - Stock Titan
How big funds are accumulating IDEAYA Biosciences Inc. (30J) stockJuly 2025 Fed Impact & AI Driven Price Forecasts - Newser
Ideaya Biosciences stock hits 52-week high at 36.57 USD - Investing.com
Is IDEAYA Biosciences Inc. (30J) stock a fit for income portfoliosGDP Growth & Weekly Top Gainers Trade List - Newser
Is IDEAYA Biosciences Inc. (30J) stock safe for risk averse investors2025 Performance Recap & AI Powered Buy and Sell Recommendations - Newser
IDEAYA Biosciences (NASDAQ:IDYA) Hits New 52-Week HighTime to Buy? - MarketBeat
Transcript : IDEAYA Biosciences, Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-02-2025 09 - marketscreener.com
Can IDEAYA Biosciences Inc. stock beat market expectations this quarter2025 Top Gainers & High Yield Stock Recommendations - Newser
Can IDEAYA Biosciences Inc. stock beat analyst upgradesWeekly Profit Recap & Reliable Volume Spike Trade Alerts - Newser
Will IDEAYA Biosciences Inc. (30J) stock hit analyst forecastsTrade Ideas & Daily Profit Maximizing Tips - Newser
IDEAYA receives FDA approval to begin IDE034 clinical trial - Yahoo
Is IDEAYA Biosciences Inc. (30J) stock good for wealth creation2025 Big Picture & Technical Buy Zone Confirmation - Newser
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS) and IDEAYA Biosciences (IDYA) - The Globe and Mail
Citi Global Healthcare Conference - marketscreener.com
Ideaya Biosciences, Inc. Announces Ind Clearance for Ide034, A Potential First-In-Class Bispecific B7h3/Ptk7 Top1 Adc Targeting Multiple Solid Tumor Types - marketscreener.com
IDEAYA receives FDA clearance for bispecific cancer drug IDE034 By Investing.com - Investing.com Nigeria
Sector Update: Health Care Stocks Decline Pre-Bell Monday - marketscreener.com
IDEAYA Biosciences stock rises after FDA clearance for bispecific ADC By Investing.com - Investing.com Nigeria
IDEAYA Biosciences stock rises after FDA clearance for bispecific ADC - Investing.com
Ideaya Biosciences Inc Stock (IDYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):